Informed consent in clinical research in France: assessment and factors associated with therapeutic misconception
- I S Durand-Zaleski1,
- C Alberti2,
- P Durieux3,
- X Duval4,
- S Gottot5,
- Ph Ravaud4,6,
- S Gainotti1,7,
- C Vincent-Genod1,
- D Moreau1,
- P Amiel8
- 1AP-HP, Henri Mondor hospital, Public Health, Faculte de Medecine, Créteil, France
- 2AP-HP, Robert Debré hospital, Clinical Epidemiology; Inserm, CIE 5, Paris, France
- 3AP-HP, Hôpital Européen Georges Pompidou, Department of Medical Informatics, Paris; Descartes University, INSERM UMRS, France
- 4AP-HP, Hôpital Bichat-Claude Bernard, Département d’Epidémiologie, Biostatistique et Recherche Clinique, Paris, France
- 5AP-HP, Robert Debré Hospital, Paris; Université Paris, Paris, France
- 6INSERM, U738, Paris; Université Paris, UFR de Médecine, Paris, France
- 7Istituto Superiore di Sanità, Rome, Italy
- 8Institut de Cancérologie Gustave-Roussy, Social and Human Sciences Research Unit, Villejuif, France
- Professor I Durand-Zaleski, AP-HP, Henri Mondor hospital, Public Health, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France; isabelle.durand-zaleski{at}hmn.aphp.fr
- Received 24 October 2007
- Revised 14 March 2008
- Accepted 3 April 2008
Abstract
Background: Informed consent in clinical research is mandated throughout the world. Both patient subjects and investigators are required to understand and accept the distinction between research and treatment.
Aim: To document the extent and to identify factors associated with therapeutic misconception in a population of patient subjects or parent proxies recruited from a variety of multicentre trials (parent studies).
Patients and methods: The study comprised two phases: the development of a questionnaire to assess the quality of informed consent and a survey of patient subjects based on this questionnaire.
Results: A total of 303 patient subjects or parent proxies were contacted and 279 questionnaires were analysed. The median age was 49.5 years, sex ratio was 1 and 61% of respondents were professionally active. Overall memorisation of the oral or written communication of informed consent was good (69–97%), and satisfaction with the process was around 70%. Therapeutic misconception was present in 70% of respondents, who expected to receive better care and ignored the consequence of randomisation and treatment comparisons. This was positively associated with the acuteness and severity of the disease.
Conclusion: The authors suggest that the risk of therapeutic misconception be specifically addressed in consent forms as an educational tool for both patients and investigators.
Footnotes
-
Competing interests: None declared.
-
Funding: This project was financed in part by a grant from the French Ministry of Health PHRC AOM98123.
-
Ethics approval: The study was approved by the ethics committee of Henri Mondor hospital, Créteil, France.







